Skip to main content

Coronavirus: Vaccination

Question for Department of Health and Social Care

UIN 7195, tabled on 25 May 2021

To ask the Secretary of State for Health and Social Care, what steps he is taking to provide funding for research into covid-19 vaccine efficacy among all types of blood cancer.

Answered on

2 June 2021

As part of the COVID-19 Immunity National Core Study, UK Research and Innovation (UKRI) is providing initial funding of £1.8 million for 12 months towards the OCTAVE study, examining the effectiveness of COVID-19 vaccines in clinically at-risk groups and £3 million towards a new research call to support projects investigating COVID-19 vaccine responses and immune failure. UKRI is also supporting the COVID-19 Data and Connectivity National Core Studies Programme with an investment of up to £15.2 million, which will enable studies including the evaluation of vaccine uptake and efficacy across all populations, including people with blood cancer.